About Alchemab
Alchemab is a company based in London (United Kingdom) founded in 2019.. Alchemab has raised $114.66 million across 5 funding rounds from investors including Lilly, Gov.uk and RA Capital. The company has 8 employees as of December 31, 2020. Alchemab offers products and services including Antibody Therapeutics. Alchemab operates in a competitive market with competitors including T3D Therapeutics, Pardes Biosciences, Alzheon, Longeveron and Vaxxinity, among others.
- Headquarter London, United Kingdom
- Employees 8 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alchemab Therapeutics Ltd
- Date of Incorporation 14 Aug, 2019
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$114.66 M (USD)
in 5 rounds
-
Latest Funding Round
$32 M (USD), Series A
Sep 09, 2025
-
Investors
Lilly
& 8 more
-
Employee Count
8
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alchemab
Alchemab offers a comprehensive portfolio of products and services, including Antibody Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments from resilient individuals' antibodies for hard-to-treat diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Alchemab
Alchemab has successfully raised a total of $114.66M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $32 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $32.0M
- First Round First Round
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series A - Alchemab | Valuation |
investors |
|
| Dec, 2022 | Amount | Grant - Alchemab | Valuation |
investors |
|
| Jun, 2021 | Amount | Grant - Alchemab | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alchemab
Alchemab has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Gov.uk and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital fund and fund of funds focused on the life science sector
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alchemab
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alchemab
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alchemab Comparisons
Competitors of Alchemab
Alchemab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Pardes Biosciences, Alzheon, Longeveron and Vaxxinity, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| domain | founded_year | HQ Location |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Provider of antibody-based therapies to monitor viral infections
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alchemab
Frequently Asked Questions about Alchemab
When was Alchemab founded?
Alchemab was founded in 2019.
Where is Alchemab located?
Alchemab is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Is Alchemab a funded company?
Alchemab is a funded company, having raised a total of $114.66M across 5 funding rounds to date.
How many employees does Alchemab have?
As of Dec 31, 2020, the latest employee count at Alchemab is 8.
What does Alchemab do?
Developer of antibody-based therapeutics to treat cancers, neurodegenerative conditions, and infectious diseases. The company is developing novel antibody therapeutic candidates by understanding the binding targets of the antibodies and replicating the action.
Who are the top competitors of Alchemab?
Alchemab's top competitors include NRx, ExeVir Bio and Alzheon.
What products or services does Alchemab offer?
Alchemab offers Antibody Therapeutics.
Who are Alchemab's investors?
Alchemab has 9 investors. Key investors include Lilly, Gov.uk, RA Capital, Innovate UK, and SV Health Investors.